Literature DB >> 12223982

Attained adult height in juvenile rheumatoid arthritis with or without corticosteroid treatment.

S-J Wang1, Y-H Yang, Y-T Lin, C-M Yang, B-L Chiang.   

Abstract

Growth impairment has been described in patients with juvenile rheumatoid arthritis (JRA). Both the direct action of underlying disease and prolonged corticosteroid usage for disease management may contribute to growth impairment. The purpose of this retrospective study was to evaluate the effect of systemic corticosteroid treatment on attained adult height in patients with JRA. We reviewed patients who first visited our hospital from 1973 to 1995 with a diagnosis of JRA. Adult height (AH) and the reported parental heights of these patients were recorded. Target height (TH) is estimated according to midparental height. Patients who never had or had only transient (less than 1 week) systemic corticosteroid therapy were classified as group 1. Group 2 included patients who had corticosteroid therapy for more than 1 week but never continuously for more than 12 months, and group 3 included patients on long-term steroid treatment (continuously for more than 1 year). Height data were analysed using adult height and the difference between adult height and target height (AH minus TH). Thirty-three patients fulfilling the diagnostic criteria for JRA were reviewed. Fourteen belonged to group 1, 13 to group 2 and six to group 3. The difference between adult height and target height in group 1 was 2.96 +/- 4.54 cm, in group 2 0.71 +/- 6.08 cm (group 1 vs. group 2, P = 0.28), and in group 3 -11.65 +/- 10.71 cm (group 1 vs. group 3, P<0.05). In 15 patients who never received corticosteroid therapy continuously for more than 1 year, AH-TH was statistically correlated neither with the cumulative corticosteroid exposure dose nor with cumulative corticosteroid exposure period by linear regression ( P = 0.408, P = 0.278, respectively). We concluded that continuous systemic corticosteroid usage for less than 1 year does not affect attained adult height in JRA patients; however, prolonged corticosteroid treatment for more than 1 year can lead to irreversible growth impairment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12223982     DOI: 10.1007/s100670200098

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

1.  Long-term outcome of 424 childhood-onset myasthenia gravis patients.

Authors:  Mengcui Gui; Xuan Luo; Jing Lin; Yue Li; Min Zhang; Xiaofan Zhang; Mingshan Yang; Wei Wang; Bitao Bu
Journal:  J Neurol       Date:  2015-01-15       Impact factor: 4.849

Review 2.  Pediatric Osteoporosis: Diagnosis and Treatment Considerations.

Authors:  Edoardo Marrani; Teresa Giani; Gabriele Simonini; Rolando Cimaz
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

Review 3.  [Juvenile rheumatoid diseases: Endoprosthetic care of destroyed hip joints].

Authors:  S Rehart; M Henniger
Journal:  Orthopade       Date:  2015-07       Impact factor: 1.087

4.  Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.

Authors:  P Tynjälä; P Lahdenne; P Vähäsalo; H Kautiainen; V Honkanen
Journal:  Ann Rheum Dis       Date:  2006-01-31       Impact factor: 19.103

5.  Longitudinal growth attainments of Indian boys with juvenile rheumatoid arthritis.

Authors:  Bimal Aggarwal; Anil K Bhalla; Surjit Singh
Journal:  Rheumatol Int       Date:  2010-01-07       Impact factor: 2.631

6.  Secondary osteoporosis in patients with juvenile idiopathic arthritis.

Authors:  Kristyna Brabnikova Maresova
Journal:  J Osteoporos       Date:  2011-02-20

7.  Growth retardation and delayed puberty in children and adolescents with juvenile idiopathic arthritis.

Authors:  Wioleta Umławska; Anna Prusek-Dudkiewicz
Journal:  Arch Med Sci       Date:  2010-03-09       Impact factor: 3.318

8.  Meta-analysis of sample-level dbGaP data reveals novel shared genetic link between body height and Crohn's disease.

Authors:  Antonio Di Narzo; Itziar Frades; Heidi M Crane; Paul K Crane; Jean-Sebastian Hulot; Andrew Kasarskis; Amy Hart; Carmen Argmann; Marla Dubinsky; Inga Peter; Ke Hao
Journal:  Hum Genet       Date:  2021-01-16       Impact factor: 5.881

Review 9.  Growth abnormalities in children with type 1 diabetes, juvenile chronic arthritis, and asthma.

Authors:  Cosimo Giannini; Angelika Mohn; Francesco Chiarelli
Journal:  Int J Endocrinol       Date:  2014-02-04       Impact factor: 3.257

10.  The association between lean mass and bone mineral content in the high disease activity group of adult patients with juvenile idiopathic arthritis.

Authors:  Kristyna Brabnikova Maresova; Katerina Jarosova; Karel Pavelka; Jan J Stepan
Journal:  BMC Musculoskelet Disord       Date:  2014-02-21       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.